- Location
phase II trial
"-
BrainStorm Cell Therapeutics Has Received a Notice of Allowance From The US Patent Office
Feb 11, 2014BrainStorm Cell Therapeutics has received a notice of allowance from the US Patent Office for its ‘Mesenchymal Stem Cells for the Treatment of CNS Diseases’ (serial number 12/994,761) patent application. This patent relates to ...
Tags: Cell Technology Patent, Medicine
-
Validive Received a Fast Track Designation for Prevention and Treatment of Oral Mucositis
Jan 26, 2014BioAlliance Pharma, an innovative Company dedicated to the development of orphan oncology, announced today that Validive (clonidine Lauriad) received a Fast Track designation from the US Food and Drug Administration (FDA) for the prevention ...
Tags: FDA, BioAlliance Pharma, disease, Validive
-
InnaVirVax Has Commenced a Phase II Clinical Trial of The VAC-3S Vaccine
Dec 5, 2013InnaVirVax, a biopharmaceutical company, has commenced a Phase II clinical trial evaluating the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy (ART) in the course of HIV-1 infection. The ...
-
JNJ and PCYC Have Won Approval From FDA for Their Breakthrough Therapy Imbruvica
Nov 15, 2013Johnson & Johnson (JNJ) subsidiary Janssen Biotech and Pharmacyclics (PCYC) have won approval from the US Food and Drug Administration (FDA) for their breakthrough therapy Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma ...
Tags: Johnson&Johnson, MCL Patients
-
Aeterna Zentaris Submitted a NDA to FDA for Its Ghrelin Agonist, Macimorelin Acetate
Nov 7, 2013Canadian biopharmaceutical firm Aeterna Zentaris has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for its ghrelin agonist, macimorelin acetate (AEZS-130), a novel orally-active small molecule. The ...
Tags: Aeterna Zentaris, Medicine
-
Alzheon Announced The Launch of The Company,The Securing of Initial Private Financing
Oct 28, 2013Alzheon announced the launch of the company, the securing of initial private financing, and the signing of an exclusive license agreement to a novel clinical drug candidate for Alzheimer’s disease, a family of analogs, and a drug ...
Tags: Alzheon, Alzheimer's Disease
-
CFFT Has Provided $1.7m Research Award to US-based Savara Pharmaceuticals
Oct 21, 2013Cystic Fibrosis Foundation Therapeutics (CFFT), an affiliate of the CF Foundation, has provided $1.7m research award to US-based Savara Pharmaceuticals for advancing the development of AeroVanc (vancomycin hydrochloride inhalation powder). ...
-
IMH Has Approved Pluristem Therapeutics' Request to Start a Phase II Trial
Oct 9, 2013The Israeli Ministry of Health (IMH) has approved Pluristem Therapeutics’ request to start a Phase II trial using its PLacental eXpanded (PLX) cells in the treatment of intermittent claudication (IC). IC is a subset of peripheral ...
Tags: clinical study, Medicine
-
Naurex Has Announced The Issuance of New US Patent for Partial Agonist
Aug 2, 2013Naurex has announced the issuance of new US patent for selective NMDA receptor partial agonist, GLYX-13, covering methods of treating major depressive disorder through 2030. In a Phase II trial, GLYX-13 demonstrated considerable safety, ...
-
Cha Bio&Diostech Has Filed Its First Investigational New Drug (IND) Application
Jul 10, 2013Cha Bio&Diostech, a South Korean partner of Pluristem Therapeutics, has filed its first investigational new drug (IND) application for Pluristem’s PLacental eXpanded (PLX) cells with the Korean Food and Drug Administration (KFDA). ...
Tags: PLX Cells, Cha Bio&Diostech
-
Activaero Has Reported The Positive Results From Its Phase II Trial in Children
Apr 15, 2013Activaero has reported the positive results from its phase II trial in children with mild to moderate asthma. The proof-of-concept trial was conducted with Activaero's drug-device combination consisting of budesonide in liquid formulation ...
Tags: Activaero, phase II trial, moderate asthma
-
Neuralstem Has Obtained Notice of Allowance for a Patent
Apr 8, 2013Neuralstem has obtained notice of allowance for a patent that covers various methods to use expanded spinal cord stem cells such as NSI-566 to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The company completed Phase ...
-
Moberg Derma Has Announced The Discontinuation of The Development of Limtop
Mar 13, 2013Moberg Derma has announced the discontinuation of the development of Limtop, an actinic keratosis drug, as it failed to reach the predefined efficacy target in a completed phase II trial. Moberg Derma president and CEO Peter Wolpert said ...
Tags: drug, Moberg Derma, actinic keratosis drug
-
Sequenta LymphoSIGHT Method Will Be Used by Eastern in E1411 Phase II Trial
Dec 18, 2012Eastern Cooperative Oncology Group, now a part of the ECOG-ACRIN Cancer Research Group, has entered into an agreement to use Sequenta's new LymphoSIGHT sequencing method in its randomized E1411 phase II trial. LymphoSIGHT is designed for ...
-
TissueGene Completes Enrolling Patients in a US-Based Phase II Trial of Its TG-C Therapy
Dec 17, 2012TissueGene has completed enrolling patients in a US-based Phase II trial of its TG-C therapy, designed to treat patients with Grade 3 chronic degenerative joint disease (DJD) of the knee. Comprising human allogeneic chondrocytes, the TG-C ...
Tags: TG-C therapy, therapeutic protein, TG-C
